Evidence Level:Sensitive: A2 - Guideline
Excerpt:Recommendation 3.2….For patients with BRAF-mutant (V600) unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order)...encorafenib plus binimetinib…
Evidence Level:Sensitive: C1 - Off-label
(Approved for Melanoma)
New
Excerpt:Encorafenib is indicated:...in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Excerpt:...- Documented evidence of a BRAF V600E or V600K mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Excerpt:...- Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Excerpt:...- Presence of BRAF V600E or V600K mutation in tumor tissue prior to randomization...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Excerpt:...- Patient must have BRAF V600 mutation positive based on report from Clinical Laboratory Improvement Act (CLIA) certified laboratory...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Excerpt:...- Available tumour sample for central determination of the BRAF V600E/K mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Excerpt:...- Presence of a BRAF V600E or V600K mutation, or both, in their tumour tissue....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Excerpt:...- Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or central laboratory -...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Encorafenib used with binimetinib versus placebo in BRAF mutant stage II melanoma after surgery to evaluate the efficacy and safety in preventingmelanoma recurrence Encorafenib utilizzato con binimetinib rispetto al placebo nel melanoma in stadio II con mutazione BRAF dopo l'intervento chirurgico per valutare l'efficacia e la sicurezza nella prevenzione recidiva del melanoma
Excerpt:...Melanoma determined locally to be V600E/K mutation-positive. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A study of binimetinib and encorafenib in patients aged 12 to 17 with a specific type of melanoma (BRAF V600-mutant melanoma) that cannot be completely removed by surgery or that has spread to other areas in the body.
Excerpt:...- Male or female 12 to < 18 years of age at the time of consent/assent.- Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer Stage IIIB, IIIC, or IV.- Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or central laboratory.- Evidence of at least one evaluable lesion (measurable or non-measurable) as detected by radiological or photographic methods based on RECIST v1.1.- Adequate cardiac function:a. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A study comparing combination of Encorafenib + Binimetinib as a standard-dose and a High-dose Regimen in patients with BRAFV600-Mutant Melanoma Brain Metastasis
Excerpt:...Presence of BRAFV600 mutation in tumor tissue previously determined by a local PCR or NGS-based assay at any time prior to Screening or by a central laboratory during Screening.5. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Excerpt:...- Presence of BRAFV600 mutation in tumor tissue previously determined by a local assay (including immunohistochemistry [IHC]) at any time prior to Screening or during Screening...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Encorafenib used with binimetinib versus placebo in BRAF mutant stage IIB/C melanoma after surgery to evaluate the efficacy and safety in preventing melanoma recurrence
Excerpt:...Molecular Pre-screening 1.Before any related study activity, written informed consent must be given according to ICH/GCP, and national/local regulations; 2.Male or female ≥ 18 years of age; 3.Surgically resected, with tumor free margins, and histologically/pathologically confirmed new diagnosis of stage II (pT3b-pT4bN0) cutaneous melanoma per AJCC 8th edition; 4.Sentinel node (SN) staged node negative (pN0); 5.Sentinel node (SN) biopsy within 14 weeks from initial diagnosis of melanoma; 6.Available tumor sample for central determination of the BRAFV600E/K mutation. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab inParticipants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed Duringor After Prior Treatment with Anti−PD-1 Therapy
Excerpt:...Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:- Male or female participants ≥18 years of age at the time of informed consent.- Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic(Stage IV) cutaneous melanoma, according to the AJCC 8th edition.- Documented evidence of a BRAF V600E or V600K mutation.- Submission of adequate tumor tissue for central laboratory testing of BRAF V600E/K mutation and biomarkers is required for all participants during the screening period and prior to randomization.- Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab orpembrolizumab).- Must have anti-PD-1 resistant disease (primary or secondary) with confirmed diseaseprogression per RECIST v1.1 either during or after receipt of an approved anti-PD-1monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according tothe SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020).- Have at least 1 measurable lesion per RECIST v1.1.- ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50%by cardiac imaging.`...
